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As the world battles COVID- 19, other long-
standing global health challenges continue 
to cause illness, suffering and death. Among 
them is the neglected crisis of snakebite 
envenoming (SBE): in the year after the 
COVID- 19 pandemic was declared, an esti-
mated 2.7 million SBE led to over 100 000 
deaths and 400 000 long- term disabilities 
in the poorest and most rural communities 
of Asia, Africa and Latin America.1 Yet the 
tools used to combat SBE remain woefully 
inadequate and underexplored, with the 
most commonly- used antivenom treatments 
still based on 19th- century technologies.
An oft- heard concern during the 
COVID- 19 crisis is that shifts in research and 
development (R&D) spending may reduce 
support for neglected tropical diseases 
(NTDs) like SBE. Indeed, in April 2020 the 
WHO issued interim guidance to postpone 
NTD programmes and activities because 
of the pandemic.2 The direct and indirect 
impacts of COVID- 19 will likely endure for 
years.
Yet at the same time, long- term opportu-
nities for SBE have also emerged. Notwith-
standing major differences in nature, 
magnitude and global visibility of these two 
public health crises, experience gained with 
COVID- 19 can be successfully applied to 
NTDs, and SBE specifically. In this article, 
we briefly recap the challenging status of 
current SBE tools and identify key lessons 
and recommendations from COVID- 19 that 
could help refocus funding and accelerate 
progression of novel SBE candidates in 
the R&D pipeline. Our aim is to highlight 
the enormous promise of finally bringing 
21st- century technologies and approaches 
to the age- old problem of SBE.
THE SBE STATUS QUO
SBE poses major unmet medical needs for 
both diagnosis and treatment, including a 
reliance on antivenoms as the cornerstone 
of treatment. While antivenoms save lives 
and prevent sequelae, they also present 
myriad challenges (see box 1). These 
range from not knowing for many patients 
what snake species was involved (key infor-
mation for selecting which serum to use) 
to the limited manufacturing capacity in 
high- burden regions—exacerbated by the 
complicated, expensive method needed 
to produce antivenoms. Additional, post-
manufacturing challenges include a lack of 
clinical testing or proper quality control for 
many circulating products as well as diffi-
culties ensuring availability and access, not 
least the need for an effective cold chain 
management system to distribute and store 
most available products.
There is clearly an urgent need for a range 
of solutions, from better- designed, quality- 
assured conventional antivenoms to novel 
diagnostics and therapeutics and robust, effi-
cient clinical testing approaches—all tailored 
to the needs of patients in low- resource 
settings.
Summary box
 ► Despite inherent differences, Snakebite Envenoming 
and COVID- 19 have much in common in terms of 
research and development (R&D) challenges and 
opportunities.
 ► Both crises require a diversified portfolio of R&D 
solutions, ranging from diagnostics to treatments, 
that can effectively work and be accessible in differ-
ent resource settings.
 ► Collaborative clinical research and streamlined reg-
ulatory pathways are critical to accelerate these 
candidates in the R&D pipeline.
 ► Transformative progress is possible with a concerted 
approach that aligns strong political will, coordinated 
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KEY COVID-19 LESSONS FOR CLOSING THE SBE R&D GAP
Need for a robust portfolio of candidate products
COVID- 19 and SBE management and control each 
require a wide variety of tools, and therefore an R&D 
pipeline with candidates based on a variety of strate-
gies—since inevitably some products will fail. As of 
December 2020, the global pipeline for COVID- 19 
candidates contained over 1000 potential new vaccines, 
therapeutics and diagnostics.3 Although we lack a 
complete picture of the SBE product pipeline, recent 
data indicate that half of R&D funding between 2007 
and 2018 focused on basic research, with the remaining 
minimal, fluctuating resources divided across biologics, 
drugs and, to a very limited extent, drugs and diagnos-
tics.4
The result is that, despite their limitations, antivenoms 
remain the only tool available in low- resource settings, 
while promising next- generation therapeutic and 
diagnostic approaches based on newer strategies languish 
in the pipeline (see table 1).
Impact of innovative pathways for research and regulatory 
approval
Innovating clinical research and streamlining regula-
tory approaches have been crucial to accelerating the 
progress of COVID- 19 candidate products. Some of the 
most successful COVID- 19 clinical trials, designed to 
produce definitive, actionable results, have been large, 
multisite, multicountry and/or consortium- based trials 
using a platform- based approach to facilitate integra-
tion and standardisation5—for example, the UK- based 
Recovery trial of treatment for hospitalised patients.6 In 
many cases, regulatory pathways were also streamlined 
and fast- tracked without compromising the robustness of 
the respective assessments. Given the scarcity of rigorous 
clinical studies on efficacy or safety of antivenoms,7 
similar collaborative approaches will be essential to effi-
ciently advance appropriate products through the R&D 
pipeline and ensure accelerated review and approval.
Importance of diversified financing and incentives for R&D
The year 2020 has shown dramatically that with enough 
resources, focus and political will, significant improve-
ments are possible far faster than with ‘business- as- usual’ 
approaches. While there are no precise numbers for world-
wide spending on COVID- 19 R&D in 2020, overall R&D 
spending in biopharma increased 23% (to US$44 billion) 
from 2019, much of which was on the new disease. Over 
US$9 billion in funding announcements had been made 
across public, philanthropic and industry partners to 
support candidate products as of October 2020.3 One year 
into the pandemic, several highly effective vaccines and 
many diagnostic products had already received market 
authorisation.
In contrast, between 2007 and 2018 global funding for 
SBE research totalled only US$57 million (a mean annual 
Box 1 Challenges with using antivenoms in snakebite 
envenoming treatment
 ► Still uses early 1900’s complex production process that cannot 
be fully standardised (isolation from hyperimmune plasma of im-
munised animals, usually horses). Technical innovations such as 
IgG and (Fab')2 purification have been introduced but not uniformly 
adopted across manufacturers.11
 ► Usually specific for one or few snake species, but products are often 
used in settings where they do not target all medically important 
species.
 ► Unknown efficacy and safety profiles for many products, few of 
which have been evaluated in robust clinical trials.7
 ► Insufficient quality control based on WHO guidelines, leading to 
many ineffective products in circulation.1
 ► Supply shortages that lead to severely limited access, especially in 
sub- Saharan Africa.1
 ► High prices, leading to potentially catastrophic cost when victims 
need to pay out of pocket.12
Table 1 Examples of promising products in the R&D pipeline for SBE
Product categories Mechanism of action Description and potential use
Small- molecule inhibitors13 Inhibition of venom phospholipase A2 
(sPLA2) enzyme
 ► Promising rapid treatment for venom- induced neurotoxicity and 
cytotoxicity
 ► Can be administered quickly, before patient accesses injectable 
antivenoms, or as adjuvant treatment
 ► Neutralisation of broad spectrum of venoms
Inhibition of venom metalloproteases  ► Inhibits haemorrhagic activity of venoms




Neutralisation of venom  ► Neutralisation of key toxins from different snake species by binding 
to conserved epitopes
 ► Creation of region- specific cocktails of a few antibodies tailored to 
local snake distribution
 ► Reduced risk of anaphylactic shock with use of humanised mAbs
Rapid diagnostic tests15 Venom- identification kits  ► Earlier diagnosis of systemic envenomations
 ► Improved identification of offending snake species
 ► More rational use of antivenoms
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investment of less than 5 million).4 According to the latest 
G- Finder report, funding for snakebite- related R&D totalled 
US$10.29 million in 2019, equivalent to only 0.3% of all 
R&D investment in neglected diseases8—although still, an 
increase of over 60% (US$3.7 m) from 2018. Much of this 
growth came from the UK, which provided three- quarters 
of all SBE global funding in 2019. Industry funding also 
doubled. Together, these increases drove a near- fourfold 
rise in funding for snakebite biologics (up US$ 5.4 million). 
Still, the total R&D investment remains quite small and is 
currently in extreme jeopardy since the UK, as the main 
investor, recently announced funding cuts effective in mid- 
2021 of up to 90% for many NTD programmes,9 decreases 
which will severely impact ongoing SBE projects. More 
broadly, this chronic underfunding has slowed progress in 
R&D for new technologies and has limited development of 
solutions to ensure that safe, effective and accessible prod-
ucts reach the markets where they are most needed.
Imperative to address inequities and priorities from resource-
limited settings
Despite the massive budgets and innovation driving 
COVID- 19 product development, a huge imbalance 
remains in mid- 2021 between high- income and low- income 
countries in availability of these tools, especially highly 
effective vaccines—and consequently in the severity of the 
pandemic. Most funding so far has strongly prioritised the 
needs of wealthy countries, and decisions have been made 
largely by people in and from these settings. Furthermore, 
though many innovations have been driven by public 
funding and/or public- interest research institutions, there 
are presently only very limited requirements known for 
transparency on R&D and manufacturing costs, or contrac-
tual requirements for equitable access. Since populations 
in poorer countries bear the overwhelming burden of SBE, 
it is crucial that R&D priorities are driven by their needs 
and decision- makers, and that investments include robust 
guarantees for access, potentially including transfer of 
manufacturing technologies and build- up of production 
capacity in high- burden regions.
CONCLUSIONS
The past year has demonstrated extraordinary global 
capacity for R&D mobilisation. Meanwhile, for both 
COVID- 19 and SBE, there have been few solutions and 
relatively little funding for the health priorities of low- 
resource settings.
Still, successes with COVID- 19 reveal tremendous 
opportunities to catalyse investments and close the R&D 
gap for snakebite. Reviving R&D for SBE must involve:
 ► A global R&D strategy which considers an end- 
to- end approach, from basic research to strategies 
for remote, marginalised communities to access 
successful products.
 ► Development of clinical trial platforms or networks 
to facilitate standardisation of methodologies, 
integration of results, and rapid assessment of new 
tools for SBE management.
 ► Streamlining regulatory pathways to facilitate R&D, 
encourage innovation and speed the approval of new 
products given the extreme, longstanding neglect of 
SBE.
 ► A coordinated investment strategy which capitalises 
on available public funding and leverages greater 
commitment from the private sector, including 
biotech firms. It should clearly link R&D objectives 
with financial incentives that promote both innova-
tion and equitable access to SBE interventions.
High- burden regions must be at the centre of 
R&D agendas, an obligation underpinning these 
recommendations.
A post- pandemic world may appear distant for most 
NTD- affected countries, given the enormous gaps in their 
access to new products that are gradually controlling the 
pandemic in high- income regions. But as NTD programmes 
resume the research community must harness newlygained 
knowledge, partnerships and collaborative approaches 
to accelerate progress towards the ambitious 2030 NTD 
targets1 10 and the reduction of health inequities. Each 
of these components will become increasingly important 
for success in achieving the WHO goal of reducing death 
and disability from SBE by 50% within a decade. That time 
approaches. We must stand ready to challenge the status 
quo and deliver transformational change.
Twitter Diogo Martins @dcorreiamartins
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